Click here to watch the video version of this podcast.
No, not that apprentice. Todd Brady, MD, PhD, turned VC/EIR (for venture capitalist, entrepreneur in residence), turned CEO of Aldeyra Therapeutics back in 2012, talks about how he transitioned from the lab to the “dark side” back in the 1990s when “industry” was still a dirty word. Todd found his calling as a company builder who has since taken Aldeyra public and into Phase III trials with novel treatments for dry eye disease, allergic conjunctivitis, and proliferative vitreoretinopathy. The company is also developing other product candidates for retinal and systemic inflammatory diseases. Listen in for some words of wisdom from the real “Apprentice.”